Opioid Response in an Individual with Altered CYP2D6 Activity:
Implications of a Pharmacogenomics Case
AbstractThe benefits of opioid use in older adults to manage chronic non-cancer
pain must outweigh the risks as these individuals are more susceptible
to the side effects and drug interactions associated with opioids.
Pharmacogenomic testing supports clinicians to select an appropriate
opioid therapy while minimizing these risks.